Expertise in
1
conditions

I-chen H. Wu

Kaohsiung, KHQ, TW 
Expertise in
1
conditions
Kaohsiung, KHQ, TW 

Overview

I-chen Wu practices practicing medicine in Kaohsiung, Taiwan.

Wu is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Esophageal Cancer, Peptic Ulcer, Watermelon Stomach, Endoscopy, and Endovascular Embolization.

They are actively involved in clinical research, co-authoring 94 peer reviewed articles and participating in 4 clinical trials.

Locations

Kaohsiung, KHQ, Taiwan
Other Locations
No. 1, Jen Ai Road, Taipei 100, TPQ, Taiwan
Tainan, TNQ, Taiwan
Taitung, TNQ 40220, Taiwan
515, Sec. 1, Jhongshan Rd, Nantou 553203, Taiwan. Yushan National Park Headquarters, Yushan, TNQ 55320, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab Paclitaxel, S1, Leucovorin, Oxaliplatin
Study Phase: Phase 2
Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2026
Intervention Type: Drug
Study Phase: Not Applicable
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients With Advanced Neuroendocrine Tumors
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients With Advanced Neuroendocrine Tumors
Enrollment Status: Active_not_recruiting
Publish Date: December 23, 2025
Intervention Type: Drug
Study Drug: CVM-1118
Study Phase: Phase 2
BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study): a Single-arm, Phase II Study
BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study): a Single-arm, Phase II Study
Enrollment Status: Completed
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drugs: BI-754091, Afatinib
Study Phase: Phase 2
View 3 Less Clinical Trials

94 Total Publications

Integrating genetic and lifestyle determinants in a risk prediction model for esophageal squamous cell carcinoma in Taiwan.
Integrating genetic and lifestyle determinants in a risk prediction model for esophageal squamous cell carcinoma in Taiwan.
Journal: Scientific reports
Published: February 24, 2026

Frequently Asked Questions about I-chen H. Wu

Is I-chen H. Wu a top-rated expert for Esophageal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. I-chen H. Wu is classified as an Distinguished expert for Esophageal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does I-chen H. Wu participate in research or clinical trials?

Yes. I-chen H. Wu has published 94 articles and abstracts on conditions like Esophageal Cancer. You can view a list of I-chen H. Wu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wu's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile